ELAN Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of -2.99% compared to Elanco Animal Health, Inc.'s net margin of 21.47%. Elanco Animal Health, Inc.'s return on equity of 0.55% beat Johnson & Johnson's return on equity of 33.27%.

Elanco Animal Health, Inc. has a consensus price target of $25.00, signalling upside risk potential of 6.52%. On the other hand Johnson & Johnson has an analysts' consensus of $212.00 which suggests that it could grow by 3.72%. Given that Elanco Animal Health, Inc. has higher upside potential than Johnson & Johnson, analysts believe Elanco Animal Health, Inc. is more attractive than Johnson & Johnson.

Elanco Animal Health, Inc. has a beta of 1.872, which suggesting that the stock is 87.178% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.341, suggesting its less volatile than the S&P 500 by 65.861%.

Elanco Animal Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.52% to investors and pays a quarterly dividend of $1.30 per share. Elanco Animal Health, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Elanco Animal Health, Inc. quarterly revenues are $1.1B, which are smaller than Johnson & Johnson quarterly revenues of $24B. Elanco Animal Health, Inc.'s net income of -$34M is lower than Johnson & Johnson's net income of $5.2B. Notably, Elanco Animal Health, Inc.'s price-to-earnings ratio is 321.95x while Johnson & Johnson's PE ratio is 19.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elanco Animal Health, Inc. is 2.54x versus 5.38x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Ligand Pharmaceuticals, Inc. has a net margin of -2.99% compared to Elanco Animal Health, Inc.'s net margin of 10.18%. Elanco Animal Health, Inc.'s return on equity of 0.55% beat Ligand Pharmaceuticals, Inc.'s return on equity of 5.72%.

Elanco Animal Health, Inc. has a consensus price target of $25.00, signalling upside risk potential of 6.52%. On the other hand Ligand Pharmaceuticals, Inc. has an analysts' consensus of $243.44 which suggests that it could grow by 17.81%. Given that Ligand Pharmaceuticals, Inc. has higher upside potential than Elanco Animal Health, Inc., analysts believe Ligand Pharmaceuticals, Inc. is more attractive than Elanco Animal Health, Inc..

Elanco Animal Health, Inc. has a beta of 1.872, which suggesting that the stock is 87.178% more volatile than S&P 500. In comparison Ligand Pharmaceuticals, Inc. has a beta of 1.007, suggesting its more volatile than the S&P 500 by 0.719%.

Elanco Animal Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ligand Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Elanco Animal Health, Inc. pays -- of its earnings as a dividend. Ligand Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Elanco Animal Health, Inc. quarterly revenues are $1.1B, which are larger than Ligand Pharmaceuticals, Inc. quarterly revenues of $115.5M. Elanco Animal Health, Inc.'s net income of -$34M is lower than Ligand Pharmaceuticals, Inc.'s net income of $117.3M. Notably, Elanco Animal Health, Inc.'s price-to-earnings ratio is 321.95x while Ligand Pharmaceuticals, Inc.'s PE ratio is 99.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elanco Animal Health, Inc. is 2.54x versus 16.19x for Ligand Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -2.99% compared to Elanco Animal Health, Inc.'s net margin of 33.68%. Elanco Animal Health, Inc.'s return on equity of 0.55% beat Merck & Co., Inc.'s return on equity of 39.63%.

Elanco Animal Health, Inc. has a consensus price target of $25.00, signalling upside risk potential of 6.52%. On the other hand Merck & Co., Inc. has an analysts' consensus of $111.62 which suggests that it could grow by 0.98%. Given that Elanco Animal Health, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Elanco Animal Health, Inc. is more attractive than Merck & Co., Inc..

Elanco Animal Health, Inc. has a beta of 1.872, which suggesting that the stock is 87.178% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.859%.

Elanco Animal Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.97% to investors and pays a quarterly dividend of $0.85 per share. Elanco Animal Health, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Elanco Animal Health, Inc. quarterly revenues are $1.1B, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Elanco Animal Health, Inc.'s net income of -$34M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Elanco Animal Health, Inc.'s price-to-earnings ratio is 321.95x while Merck & Co., Inc.'s PE ratio is 14.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elanco Animal Health, Inc. is 2.54x versus 4.36x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Zoetis, Inc. has a net margin of -2.99% compared to Elanco Animal Health, Inc.'s net margin of 30.04%. Elanco Animal Health, Inc.'s return on equity of 0.55% beat Zoetis, Inc.'s return on equity of 52.95%.

Elanco Animal Health, Inc. has a consensus price target of $25.00, signalling upside risk potential of 6.52%. On the other hand Zoetis, Inc. has an analysts' consensus of $158.22 which suggests that it could grow by 24.41%. Given that Zoetis, Inc. has higher upside potential than Elanco Animal Health, Inc., analysts believe Zoetis, Inc. is more attractive than Elanco Animal Health, Inc..

Elanco Animal Health, Inc. has a beta of 1.872, which suggesting that the stock is 87.178% more volatile than S&P 500. In comparison Zoetis, Inc. has a beta of 0.970, suggesting its less volatile than the S&P 500 by 2.953%.

Elanco Animal Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zoetis, Inc. offers a yield of 1.57% to investors and pays a quarterly dividend of $0.50 per share. Elanco Animal Health, Inc. pays -- of its earnings as a dividend. Zoetis, Inc. pays out 32.86% of its earnings as a dividend. Zoetis, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Elanco Animal Health, Inc. quarterly revenues are $1.1B, which are smaller than Zoetis, Inc. quarterly revenues of $2.4B. Elanco Animal Health, Inc.'s net income of -$34M is lower than Zoetis, Inc.'s net income of $721M. Notably, Elanco Animal Health, Inc.'s price-to-earnings ratio is 321.95x while Zoetis, Inc.'s PE ratio is 21.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Elanco Animal Health, Inc. is 2.54x versus 6.05x for Zoetis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.